CS

Castle Biosciences IncNASDAQ CSTL Stock Report

Last reporting period 30 Sep, 2024

Updated 20 Nov, 2024

Last price

Market cap $B

0.811

Micro

Exchange

XNAS - Nasdaq

CSTL Stock Analysis

CS

Uncovered

Castle Biosciences Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

75/100

Moderate score

Market cap $B

0.811

Dividend yield

Shares outstanding

26.576 B

Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The company is headquartered in Friendswood, Texas and currently employs 542 full-time employees. The company went IPO on 2019-07-25. The firm is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes. Its portfolio consists of tests for skin cancers, uveal melanoma, Barrett’s esophagus and mental health conditions. Additionally, the Company has research and development programs for tests in other diseases with high clinical need, including its test in development to predict systemic therapy response in patients with moderate-to-severe psoriasis, atopic dermatitis and related conditions. Its products include DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, myPath Melanoma, DecisionDx DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME, TissueCypher and IDgenetix. DecisionDx-Melanoma is a gene expression profile test developed to identify the risk of metastasis in patients with invasive cutaneous melanoma.

View Section: Eyestock Rating